Expertise in
5
conditions

Angela L. Genge

Montreal, QC, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Montreal, QC, CA 

Overview

Angela Genge practices in Montreal, Canada. Ms. Genge is highly rated in 5 conditions, according to our data. Her top areas of expertise are Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Dysarthria, and Myasthenia Gravis.

Her clinical research consists of co-authoring 117 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Montreal, QC, Canada
Other Locations
Montreal, Canada
Quebec, QC, Canada
Edmonton, AB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Masitinib, Riluzole
Study Phase: Phase 3
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2026
Intervention Type: Drug
Study Drug: MN-166
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of Fosigotifator in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of Fosigotifator in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension
Enrollment Status: Terminated
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drug: ABBV-CLS-7262
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug, Other
Study Drug: IONIS MAPTRx
Study Phase: Phase 1
A Prospective, Multi-center, Observational Study of the Safety, Tolerability and Effectiveness of SPINRAZA® (Nusinersen) in Adult Patients With Spinal Muscular Atrophy
A Prospective, Multi-center, Observational Study of the Safety, Tolerability and Effectiveness of SPINRAZA® (Nusinersen) in Adult Patients With Spinal Muscular Atrophy
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Other, Drug
A Randomized, Double-blind, Parallel Group, Single Centre, Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Orally Administered Doses of Enoxacin (200mg Twice Daily, 400mg Twice Daily and 600mg Twice Daily) in Adults With Amyotrophic Lateral Sclerosis
A Randomized, Double-blind, Parallel Group, Single Centre, Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Orally Administered Doses of Enoxacin (200mg Twice Daily, 400mg Twice Daily and 600mg Twice Daily) in Adults With Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drug: Enoxacin
Study Phase: Phase 1/Phase 2
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Drug
Study Phase: Phase 2
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Enrollment Status: Terminated
Publish Date: August 24, 2023
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 3
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations
A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations
Enrollment Status: Completed
Publish Date: April 24, 2020
Intervention Type: Biological
Study Phase: Phase 3
View 9 Less Clinical Trials

117 Total Publications

ALS motor phenotypes: a revised 'OPM' classification.
ALS motor phenotypes: a revised 'OPM' classification.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: March 17, 2026

Frequently Asked Questions about Angela L. Genge

Is Angela L. Genge a top-rated expert for Primary Lateral Sclerosis?

MediFind is an objective health platform that identifies experts based on real-world data. Angela L. Genge is classified as an Elite expert for Primary Lateral Sclerosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Angela L. Genge participate in research or clinical trials?

Yes. Angela L. Genge has published 117 articles and abstracts on conditions like Primary Lateral Sclerosis. You can view a list of Angela L. Genge's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Genge's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile